40 likes | 348 Views
Soft Tissue Friendly Design. ? Clinical experience with less invasive surgery techniques in total knee arthroplasty: A comparative study.Kashyap, SN
E N D
1. Vanguard Clinical Results
3. Restore Function and Range of Motion ? A Single TKA System with Broad Size and Constraint Options Improves Outcomes for Both Men and Women
Lombardi AV et al, 2009, AAOS 2009 Annual Meeting, February 25-28, Las Vegas, Proceedings p.575, Scienti Ex No. SE28
- 1902 primary TKR with mean follow up of 2 months
- Both genders post-operative ROM improved, post-operative KS pain, clinical and functional scores
- Conclude a single TKA system with a wide variety of sizing and constraint options can provide consistently excellent results for both men and women undergoing TKA.
? The Relationship Between Pre- and Post op Range of Motion Utilizing Three Cruciate-Retaining Total Knee Prostheses
Stormont, MD et al 2009 (TBC) Journal of Investigative Surgery 2009
- 2 years follow showed increased flexion with Vanguard at 6 months (113º v 106º)
? The Relationship Between Pre- and Postoperative Range of Motion Utilizing Three Cruciate-Retaining Knee Prostheses: 203 Patients
Lombardi AV 2006, Clinical Orthopaedics and Related Research, Number 452, pp. 117–122
- Refined Perioperative protocols in combination with a less invasive, mini-arthrotomy approach using special instrumentation resulted in earlier discharge to home, higher range of motion and improved clinical and pain scores.
- 6 week flexion 111º v 105º
- Higher proportion of patients reached 120º by week 6
4. Outlive the Patient ? Wear Analysis of GUR1050 inserts (Vanguard) and Hi-fax 1900
Clarke I, Journal of Biomedical Materials Research Part B: Applied Biomaterials 2007 jbm.b.30948
- This wear study demonstrated that GUR1050 inserts were indistinguishable from the Hi-fax 1900 in terms of laboratory wear performance
- Given the excellent clinical history of DCM Hi-fax 1900, the GUR1050 should be an ideal candidate for TKR.
? A report into Functionality and Survivorship to date.
Biomet INC 2008, Data on file
- 376 patients, Single surgeon series
- 100 % survivorship @ 3 years (excluding infection) CI 95%
- 99.7% survivorship @ 3 years (including infections)
- 1 revision due to infection
? Multi-centre Prospective Clinical Evaluation (2008)
Biomet INC 2006, Data on file
- 393 patients, 18 surgeons
- 100% survivorship @ 1 year (excluding infection) CI 95%
- Mean survivorship 99.1% (including infection)
- 1 revision due to infection